ArticleFrontiers in oncology2025
Endometrial carcinosarcoma in a young female with absence of established risk factors: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinosarcoma is a rare, aggressive uterine malignancy, usually affecting postmenopausal women with recognised risk factors such as prolonged unopposed oestrogen exposure, tamoxifen use, pelvic irradiation, or high BMI. We report a 21-year-old Chinese woman with no known risk factors who presented with persistent vaginal bleeding, anaemia, and lower abdominal pain. Investigations showed microcytic hypochromic anaemia, elevated CA125, CA153, CA199, and Human Epididymis Protein 4, and pelvic MRI revealed a malignant endometrial lesion with vaginal involvement and lymphadenopathy. Biopsy confirmed carcinosarcoma with grade 3 endometrioid carcinoma as the epithelial component. Multidisciplinary review recommended extensive laparoscopic hysterectomy with bilateral adnexectomy, lymphadenectomy, and omentectomy, followed by six cycles of paclitaxel-carboplatin chemotherapy. Histology confirmed the diagnosis, and two-year follow-up showed no recurrence; a postoperative vesicovaginal fistula was surgically repaired. This atypical case in a young, underweight woman without established risk factors challenges current epidemiological assumptions and emphasises the importance of broad diagnostic consideration, timely referral, and comprehensive management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.